Table 3.

Prevalence of adverse effects overall and by health-related quality of life

Adverse Effects	All Respondents (n = 151)	Worse Quality of life (n = 72)	Better Quality of Life (n = 79)	P Value
Local, median (IQR)	4 (2–6)	4 (2–6)	3 (2–6)	0.24
Dry mouth	69.5%	76.4%	63.3%
Nasal congestion or drip	61.6%	63.9%	59.5%
Dry nose	53.0%	52.8%	53.2%
Hoarseness	36.4%	41.7%	31.6%
Nasal bleeding	31.8%	27.8%	35.4%
Pain or soreness in nose	27.2%	26.4%	27.8%
Worsened or changed sense of smell	21.9%	25.0%	19.0%
Worsened or changed sense of taste	19.9%	23.6%	16.5%
Irritated skin or chafing	19.2%	22.2%	16.5%
Pain or soreness in throat	15.2%	19.4%	11.4%
Dental issues	13.9%	20.8%	7.6%
Pain or soreness in mouth	11.3%	11.1%	11.4%
Systemic, median (IQR)	3 (1–5)	4 (2–6)	3 (1–4)	<0.001
Increased tiredness	57.0%	62.5%	51.8%
Increased amount of phlegm	50.3%	66.7%	35.4%
Increased thirst	47.0%	48.6%	45.6%
Cough	45.7%	63.9%	29.1%
Difficulty sleeping	34.4%	40.3%	29.1%
Dizziness	28.5%	36.1%	21.5%
Reduced appetite	27.2%	37.5%	17.7%
Headache during other parts of the day	20.0%	26.4%	13.9%
Morning Headache	18.5%	25.0%	12.7%
Practical, median (IQR)	1 (0–1)	1 (1–1)	1 (0–1)	0.55
Reduced mobility or physical activity	70.9%	73.6%	68.4%
Trip or fall due to oxygen equipment	11.9%	12.5%	11.4%
Burn injury or fire	0.6%	0.0%	1.3%
Social, median (IQR)	0 (0–1)	0 (0–1)	0 (0–1)	0.21
Sense of loneliness or social isolation	35.1%	41.7%	29.1%
Sense of shame	14.7%	15.3%	13.9%
Total number of adverse effects, median (IQR)	8 (4–12)	9 (5–13)	7 (3–11)	0.011

Definition of abbreviation: IQR = interquartile range.

Bold numbers denote the median number of experienced adverse effects in each category. Median number of adverse effects were compared between patients with better and worse health-related quality of life using Mann-Whitney U tests.